Bringing down the ROS: a new therapeutic approach for PPHN AJP-Lung Physiology (subscription) - 48 minutes ago Ventilation with high levels of oxygen or inhaled nitric oxide (NO) are typical strategies for improving the extracorporeal membrane oxygen, although they ...
Ikaria(R) Named Private Company of the Year by New Jersey ... MarketWatch - Nov 21, 2008 Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric...
Researchers Paving the Way for New Heart Disease Treatments University of Arizona News (press release), AZ - Aug 1, 2008 Nitric oxide is found in our bodies as well. "Our cells use it to regulate huge amounts of our physiology," Montfort said. Among other things, nitric oxide...
Ikaria's INOflo (Nitric Oxide) for Inhalation Approved in Japan Earthtimes (press release), UK - Jul 21, 2008 Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric...
GeNOsys Board of Directors? Chairman and Medical Director Present ... Business Wire (press release), CA - Jul 31, 2008 Company management presented information related to GeNOsys? successful research and development of its patented and patent pending generated Nitric Oxide...
Source: Google News
Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly - JS Beckman, WH Koppenol - American Journal of Physiology- Cell Physiology, 1996 - Am Physiological Soc ...Nitricoxide persists in solution for several minutes in micromolar concentrations
before it ... with oxygen to form much stronger oxidants like nitrogen dioxide. ...
Nitric oxide: physiology, pathophysiology, and pharmacology. - S Moncada, RM Palmer, EA Higgs - Pharmacol Rev, 1991 - ncbi.nlm.nih.gov 1991 Jun;43(2):109-42. Click here to read Nitricoxide: physiology, pathophysiology,
and pharmacology. Moncada S, Palmer RM, Higgs EA. ... Substances: NitricOxide. ...
Nitric oxide as a secretory product of mammalian cells. - C Nathan - FASEB J, 1912 - ncbi.nlm.nih.gov FASEB J. 1992 Sep;6(12):3051-64. Click here to read Nitricoxide as a secretory
product of mammalian cells. Nathan C. Beatrice and ...
The L-arginine-nitric oxide pathway - S Moncada, A Higgs - New Engl J Med, 1993 - content.nejm.org ... Next Next. The L-Arginine-NitricOxide Pathway. Salvador Moncada, and Annie Higgs. ... Nitricoxide and cardiopulmonary hemodynamics in Tibetan highlanders. J. Appl. ...
Vascular endothelial cells synthesize nitric oxide from L-arginine - RMJ Palmer, DS Ashton, S Moncada? - Nature, 1988 - palgrave-journals.com Vascular endothelial cells synthesize nitricoxide from L-arginine. ...Nitricoxide
was detected by bioassay 5 , chemiluminescence 1 or by mass spectrometry. ...
Source: Google Scholar
Inhaled nitric oxide can benefit some preemies
NEW YORK (Reuters Health) - Infants born prematurely are at increased risk for a chronic lung disease, called bronchopulmonary dysplasia, associated with prolonged use of oxygen therapy or a respirator.
Now, new research suggests that adding nitric oxide (NO) to the air they breathe can reduce that risk in some infants, and may also improve other outcomes, according to two papers in The New England Journal of Medicine.Although NO is effective in treating lung disease in full-term infants, recent studies of premature infants have produced divergent results, Dr. Roberta A. Ballard, from Children's Hospital in Philadelphia, and her associates point out in the first study.To further assess this treatment, Ballard's group included in their multicenter study nearly 600 preterm infants who required a respirator between 7 and 21 days of age. The patients were treated at one of 21 infant intensive care units in the US.
The patients were randomly selected to receive NO beginning on day 7 and continued for at least 24 days, or inactive "placebo" treatment.
Compared with infants given placebo, those treated with NO were less likely to develop bronchopulmonary dysplasia and were discharged earlier and required supplemental oxygen therapy for a shorter period.
No side effects from inhaled NO were seen.
The second study, led by Dr. John P. Kinsella at Children's Hospital in Denver, was similar to that by Ballard's group. The subjects included 793 preemies who required a respirator.
The infants were randomly assigned to placebo or inhaled NO for 21 days or until they were successful weaned off of the respirator. Treatment was begun within 48 hours of birth and lasted for around 14 days.
Overall, there was no significant difference between groups in survival or the development of bronchopulmonary dysplasia. However, inhaled NO did seem to reduce the occurrence of bronchopulmonary dysplasia among infants weighing between 1000 and 1250 grams.
NO therapy also seemed to protect against a number of potentially serious neurologic conditions, such as bleeding within the brain.
Ballard's team compared the two studies to determine factors that could account for their different outcomes. They found that in their study, NO therapy was started no sooner than 7 days after birth, versus starting on day 1 or 2 in the group led by Kinsella. The duration as well as the peak and total dose of NO were also higher.
SOURCE: The New England Journal of Medicine, July 27, 2006.
